Increased the risk of heart failure and comorbidities in patients with gout treatment: a population-based cohort study

• Published in: Annals of translational medicine 2020-04, Vol.8 (7), p.462-462
• Main Authors: Chen, Hsin-Hung, Hsieh, Ming-Chia, Ho, Chun-Wei, Chen, Ching-Chu, Hsu, Sheng-Pang, Chang, Shih-Sheng, Lin, Cheng-Li, Kao, Chia-Hung
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2305-5839; 2305-5839
• DOI: 10.21037/atm.2020.03.124

To investigate the association between gout treatment and heart failure (HF). Patients with gout between 2000 and 2010 constituted the gout cohort. The main outcome was a new diagnosis of HF. Multivariable Cox proportional hazard regression models were used to measure the effect of gout on the risk of developing HF. The Kaplan-Meier method was used to estimate the cumulative HF incidence curve for the gout and nongout cohorts. The cohort study included 50,166 patients with gout. The incidence of HF was 1.96 times higher in the gout cohort than the non-gout cohort (7.11 3.63 per 10,000 person-years). The adjusted HR of developing HF was a 1.06-fold increase (95% CI: 1.06-1.07) with age and a 1.08-fold increase for women compared with men (95% CI: 1.02-1.14). HF incidence was higher in patients with receiving any two or more types of anti-gout drug treatment. Our study revealed that gout could increase the risk of HF. Gout treatment in Taiwan cannot improve HF and actually increase the risk for HF after combination therapy for gout. The public health burden of gout should be resolved in the future.